Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin

References

• Dworkin RH, O’Connor AB, Kent J, et al. International Association for the Study of Pain Neuropathic Pain Special Interest Group. Interventional management of neuropathic pain: neuPSIG recommendations. Pain. 2013;154:2249–2261.
   PubMed Web of Science ®Google Scholar
• van Hecke O, Austin SK, Khan RA, et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155:654–662.
   PubMed Web of Science ®Google Scholar
• Locke AB, Kirst N, Shultz CG. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. Am Fam Physician. 2015;91:617–624.
   PubMed Web of Science ®Google Scholar
• Haller H, Cramer H, Lauche R, et al. The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review. BMC Psychiatry. 2014;14:128.
   PubMed Web of Science ®Google Scholar
• Doth AH, Hansson PT, Jensen MP, et al. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain. 2010;149:338–344.
   PubMed Web of Science ®Google Scholar
• Pérez C, Navarro A, Saldaña MT, et al. Modeling the predictive value of pain intensity on costs and resources utilization in patients with peripheral neuropathic pain. Clin J Pain. 2015;31:273–279.
   PubMed Web of Science ®Google Scholar
• Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25:72–90.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Travers K, Wyrwich KW, et al. Humanistic and economic burden of generalized anxiety disorder in North America and Europe. J Affect Disord. 2012;140:103–112.
   PubMed Web of Science ®Google Scholar
• Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep. 2012;16:191–198.
   PubMed Web of Science ®Google Scholar
• Darbà J, Kaskens L, Pérez C, et al. Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective. Adv Ther. 2014;31:1–29.
   PubMed Web of Science ®Google Scholar
• Davit B, Braddy AC, Conner DP, et al. International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences. AAPS J. 2013;15:974–990.
   PubMed Web of Science ®Google Scholar
• van der Meersch A, Dechartres A, Ravaud P. Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review. PLoS One. 2011;6:e23611.
   PubMed Web of Science ®Google Scholar
• Dunne SS. What do users of generic medicines think of them? A systematic review of consumers’ and patients’ perceptions of, and experiences with, generic medicines. Patient. 2016;9:499–510.
   PubMedGoogle Scholar
• Atif M, Azeem M, Sarwar MR. Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature. Springerplus. 2016;5:182.
   PubMedGoogle Scholar
• Puig-Junoy J. Policies encouraging price competition in the generic drug market: lessons from the European experience. Gac Sanit. 2010;24:193–199.
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Navarro-Artieda R. Influencia de la sustitución de medicamentos de marca por genéricos en el cumplimiento terapéutico de la hipertensión arterial y dislipemia. Gac Sanit. 2010;24:473–482.
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Physicians’ N-AR. patients’ opinions on the use of generic drugs. J Phar Pharmacother. 2012;3:268–270.
   PubMedGoogle Scholar
• Choudhry NK, Denberg TD, Qaseem A. Clinical Guidelines Committee of American College of Physicians. Improving adherence to therapy and clinical outcomes while containing costs: opportunities from the greater use of generic medications: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2016;164:41–49.
   PubMed Web of Science ®Google Scholar
• Lumbreras B, López-Pintor E. Impact of changes in pill appearance in the adherence to angiotensin receptor blockers and in the blood pressure levels: a retrospective cohort study. BMJ Open. 2017;7:e012586.
   PubMed Web of Science ®Google Scholar
• Lamberts H, Wood M, Hofmans-Okkes ÍM, eds. The International Classification of Primary Care in the European Community. With a multi-language layer. Oxford: Oxford University Press; 1993.
   Google Scholar
• The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD): World Health Organization. [cited 2017 Jul 10]. Available at: http://www.who.int/classifications/atcddd/en/
   Google Scholar
• Kazis LE, Anderson JJ, et al. Effect sizes for interpreting changes in health status. Med care. 1989;27:S178–S189.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Sicras-Mainar A, Navarro-Artieda R. Adjusted clinical groups: a patient classification system through risk adjustment. Rev Peru Med Exp Salud Publica. 2013;30:308–314.
   PubMedGoogle Scholar
• Benner JS, Pollack MF, Smith TW, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:451–461.
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Estadística 2017. Encuesta de costes laborales del año 2016. [cited 2017 Jul]. Available from http://www.ine.es/infoine
   Google Scholar
• Chaffee A, Yakuboff M, Tanabe T. Responsiveness of the VAS and McGill Pain Questionnaire in measuring changes in musculoskeletal pain. J Sport Rehabil. 2011;20:250–255.
   PubMed Web of Science ®Google Scholar
• Thompson E. Hamilton rating scale for anxiety (HAM-A). Occup Med (Lond). 2015;65:601.
   PubMed Web of Science ®Google Scholar
• Berger ML, Mamdani M, Atkins D, et al. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force report – Part I. Value Health. 2009;12:1044–1052.
   PubMed Web of Science ®Google Scholar
• Garrison LP Jr, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health. 2007;10:326–335.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ. 2013;346:f1049.
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R. Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain. Clinicoecon Outcomes Res. 2015;7:299–312.
   PubMed Web of Science ®Google Scholar
• Wettermark B, Brandt L, Kieler H, et al. Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment. Int J Clin Pract. 2014;68:104–110.
   PubMed Web of Science ®Google Scholar
• Kesselheim AS, Misono AS, Shrank WH, et al. Variations in pill appearance of antiepileptic drugs and the risk of non-adherence. JAMA Intern Med. 2013;173:202–208.
   PubMed Web of Science ®Google Scholar
• Gasser UE, Fischer A, Timmermans JP, et al. Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar®/Prolopa®. BMC Pharmacol Toxicol. 2013;14:24.
   PubMed Web of Science ®Google Scholar
• Narayanaswamy A, Neog A, Baskaran M, et al. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol. 2007;55:127–131.
   PubMedGoogle Scholar
• Steinman MA, Sands LP, Covinsky KE. Self-restriction of medications due to cost in seniors without prescription coverage. J Gen Intern Med. 2001;16:793–799.
   PubMed Web of Science ®Google Scholar
• Weissenfeld J, Stock S, Lüngen M, et al. The nocebo effect: a reason for patients’ non-adherence to generic substitution? Pharmazie. 2010;65:451–456.
   PubMed Web of Science ®Google Scholar
• Kleinman NL, Sadosky A, Seid J, et al. Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin. Epilepsy Res. 2012;102:13–22.
   PubMed Web of Science ®Google Scholar
• Cheng N, Rahman MM, Alatawi Y, et al. Mixed approach retrospective analyses of suicide and suicidal ideation for brand compared with generic central nervous system drugs. Drug Saf. 2018;41:363–376.
   PubMed Web of Science ®Google Scholar
• Leclerc J, Blais C, Rochette L, et al. Impact of the commercialization of three generic angiotensin ii receptor blockers on adverse events in Quebec, Canada: a population-based time series analysis. Circ Cardiovasc Qual Outcomes. 2017;10:Pii: e003891.
   PubMed Web of Science ®Google Scholar
• Hsu CW, Lee SY, Wang LJ. Comparison of the effectiveness of brand-name and generic antipsychotic drugs for treating patients with schizophrenia in Taiwan. Schizophr Res. 2018;193:107–113.
   PubMed Web of Science ®Google Scholar
• Tran YB, Frial T, Miller PS. Statin’s cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins. Can J Clin Pharmacol. 2007;14:e205–14.
   PubMedGoogle Scholar
• Gagne JJ, Choudhry NK, Kesselheim AS, et al. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med. 2014;161:400–407.
   PubMed Web of Science ®Google Scholar
• Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs. 2010;70:605–621.
   PubMed Web of Science ®Google Scholar
• Manzoli L, Flacco ME, Boccia S, et al. Generic versus brand-name drugs used in cardiovascular diseases. Eur J Epidemiol. 2016;31:351–368.
   PubMed Web of Science ®Google Scholar
• Unnanuntana A, Jarusriwanna A, Songcharoen P. Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment. PLoS One. 2017;12:e0180325.
   PubMed Web of Science ®Google Scholar
• Mano Y, Fukushima S, Kuroda H, et al. Adherence to changing from brand-name to generic atorvastatin in newly treated patients: a retrospective cohort study using health insurance claims. J Pharm Health Care Sci. 2015;1:12.
   PubMed Web of Science ®Google Scholar
• Loch A, Bewersdorf JP, Kofink D, et al. Generic atorvastatin is as effective as the brand-name drug (LIPITOR) in lowering cholesterol levels: a cross-sectional retrospective cohort study. BMC Res Notes. 2017;10:291.
   PubMedGoogle Scholar
• Candido KD, Chiweshe J, Anantamongkol U, et al. Can chronic pain patients be adequately treated using generic pain medications to the exclusion of brand-name ones? Am J Ther. 2016;23:e489–97.
   PubMed Web of Science ®Google Scholar
• Fraeyman J, Peeters L, Van Hal G, et al. Consumer choice between common generic and brand medicines in a country with a small generic market. J Manag Care Spec Pharm. 2015;21:288–296.
   PubMed Web of Science ®Google Scholar
• Colombo GL, Agabiti-Rosei E, Margonato A, et al. Impact of substitution among generic drugs on persistence and adherence: a retrospective claims data study from 2 local healthcare units in the Lombardy region of Italy. Atheroscler Suppl. 2016;21:1–8.
   PubMed Web of Science ®Google Scholar
• Navarro-Artieda R, Rejas-Gutiérrez J, Pérez-Paramo M, et al. Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: the effects of age and sex. Neurologia. 2018;33:141–153.
   PubMed Web of Science ®Google Scholar